2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
14
Other hematologic neoplasm
12
Gastrointestinal
7
Plasma cell
5
CNS
5
Thoracic
4
Myeloid
4
Dermatologic
4
Breast
3
Sarcoma
2
Head & Neck
2
Gynecologic
2
Genitourinary
2
Classical hematology
2
Tumor-Agnostic
1
Other solid neoplasm
1
Other neoplasm
1
Conditions
Mesothelioma, Malignant
1
Mesothelioma
1
Interventions
Cisplatin
147
pembrolizumab
129
Carboplatin
126
Injections
108
Pemetrexed
99
Paclitaxel
97
Gemcitabine
85
Irinotecan
75
Cyclophosphamide
72
Nivolumab
71
Docetaxel
68
Bevacizumab
59
Oxaliplatin
50
Fluorouracil
50
Capecitabine
48
atezolizumab
46
Leucovorin
42
Etoposide
42
tislelizumab
40
toripalimab
36
fludarabine
32
Drug Therapy
32
Ipilimumab
30
Topotecan
29
durvalumab
28
Vincristine
27
Specimen Handling
27
Early Intervention, Educational
27
Radiotherapy
26
Interviews as Topic
26
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Influenza Vaccines
×
Other solid neoplasm
×
Clear all
NCT07510815
2026-04-06
DUAL-MESO-NK
Beijing Biotech
Phase 1/2
Recruiting
36 enrolled